Podcasts
Listen to the latest oncology news from international experts
The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Genotyping in lung cancer and multi-cancer detection
Using precision genotyping for identifying resistance mechanisms in advanced lung cancer can help guide treatment decisions and prolong the benefit of targeted therapy. Advancements in the use of circulating tumor cell-free DNA (cfDNA) has simplified this procedure to look for multiple mutations, although further tests are usually needed to confirm the mutation present.
The use of cfDNA has also been evaluated for the detection of multiple cancer types, and a recent publication in the Annals of Oncology showed that over 50 cancer subtypes can be successfully detected, paving the way for earlier detection, earlier treatment and potentially higher survival rates.
In this podcast, Geoffrey Oxnard, MD, Dana-Farber Cancer Institute, Boston, MA, firstly discusses the use of liquid biopsy in genotyping for resistance mechanisms in lung cancer, the importance of genotyping patients upfront and some practical comments on sequencing of biopsies and treatment. Dr Oxnard also discusses the data from the multi-detection of cancers study.
This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
Date: 1st July 2020
